Ratings Alnylam Pharmaceuticals, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 17:04:04 13/06/2025 BST			5-day change	1st Jan Change
306.81 ^USD	+0.70%		+1.93%	+30.31%

06-09	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09:20 AM
06-09	Alnylam Gets EU Approval for RNAi Drug to Treat Transthyretin Amyloidosis With Cardiomyopathy	MT

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Source: Surperformance

Source: MSCI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Capi.($)
ALNYLAM PHARMACEUTICALS, INC.	-	-	39.73B
ELI LILLY AND COMPANY			729B
JOHNSON & JOHNSON			377B
NOVO NORDISK A/S			358B
ABBVIE INC.			340B
ROCHE HOLDING AG			269B
NOVARTIS AG			236B
ASTRAZENECA PLC			232B
MERCK & CO., INC.			205B
AMGEN INC.			160B
Average			294.59B
Weighted average by Cap.